Rachel A Crossley1, Alyssa Matz2, Terry Dew3, Ashley Kalinauskas3, Nicole Faucette1, Brad Poff3, Lawrence K Silbart2, Mark A Suckow4,5. 1. Department of Pathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, CT, U.S.A. 2. Department of Molecular and Cell Biology, College of Liberal Arts and Sciences, University of Connecticut, Storrs, CT, U.S.A. 3. Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A. 4. Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A. msuckow@uky.edu. 5. Department of Biomedical Engineering, University of Kentucky, Lexington, KY, U.S.A.
Abstract
BACKGROUND/AIM: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. MATERIALS AND METHODS: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. RESULTS: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. CONCLUSION: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer. Copyright
BACKGROUND/AIM: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. MATERIALS AND METHODS: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. RESULTS: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. CONCLUSION: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer. Copyright
Authors: Michael D Lucroy; Ryan M Clauson; Mark A Suckow; Ferris El-Tayyeb; Ashley Kalinauskas Journal: BMC Vet Res Date: 2020-11-18 Impact factor: 2.741
Authors: Michael D Lucroy; Alexa M Kugler; Ferris El-Tayyeb; Ryan M Clauson; Ashley E Kalinauskas; Mark A Suckow Journal: J Feline Med Surg Date: 2021-07-30 Impact factor: 1.971